Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Name:	us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Cash received for dividends and interest on the entity's equity and debt investments during the current period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

Name:	us-gaap_ProceedsFromInterestAndDividendsReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Adjustments to transaction price for performance obligations.

No definition available.

Name:	vtvt_AdjustmentsToTransactionPriceForPerformanceObligations
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Funding received.

No definition available.

Name:	vtvt_FundingReceived
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

License fee received.

No definition available.

Name:	vtvt_LicenseFeeReceived
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Maximum funding percentage of research and development milestones.

No definition available.

Name:	vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones
Namespace Prefix:	vtvt_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Maximum research funding receivable based on achievement of research and development milestones.

No definition available.

Name:	vtvt_MaximumResearchFundingReceivableBasedOnAchievementOfResearchAndDevelopmentMilestones
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Maximum sponsoring contribution amount.

No definition available.

Name:	vtvt_MaximumSponsoringContributionAmount
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Potential development and regulatory milestone payments receivable.

No definition available.

Name:	vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Potential regulatory milestone payments receivable upon regulatory approval.

No definition available.

Name:	vtvt_PotentialRegulatoryMilestonePaymentsReceivableUponRegulatoryApproval
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Potential sales milestone payments receivable.

No definition available.

Name:	vtvt_PotentialSalesMilestonePaymentsReceivable
Namespace Prefix:	vtvt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=vtvt_ReneoPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_OtherCommitmentsAxis=vtvt_PhaseTwoMultiRegionalClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_OtherCommitmentsAxis=vtvt_JointDevelopmentCommitteeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=vtvt_NewsoaraBiopharmaCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=vtvt_LicenseAndTechnologyTransferServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=vtvt_AnterisBioIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: